Philips launches Transcend Plus for EPIQ CVx and Affiniti CVx, delivering breakthrough image quality and FDA-cleared AI enhancements in cardiovascular ultrasound
Philips (NYSE:PHG) has unveiled Transcend Plus, a significant upgrade to its EPIQ CVx and Affiniti CVx cardiovascular ultrasound systems. The new platform features FDA-cleared enhancements in 2D and 3D imaging quality and 26 AI-enabled clinical applications - the highest number in the industry.
Key innovations include the new 2D Auto EF Advanced feature, which expands AI capabilities for contrast images, and improved visualization tools for cardiac anatomy and function. The system is designed to help cardiology teams manage increasing patient volumes and clinical complexity while maintaining diagnostic accuracy, particularly in left ventricular function assessment.
Transcend Plus will be showcased at the European Society of Cardiology 2025 Congress and the American Society of Echocardiography annual meeting.
Philips (NYSE:PHG) ha presentato Transcend Plus, un importante aggiornamento per i sistemi di ecografia cardiovascolare EPIQ CVx e Affiniti CVx. La nuova piattaforma introduce miglioramenti nell'imaging 2D e 3D approvati dalla FDA e 26 applicazioni cliniche basate su AI, il maggior numero del settore.
Tra le novità principali c'è la funzione 2D Auto EF Advanced, che estende le capacità di intelligenza artificiale anche alle immagini con contrasto, oltre a strumenti di visualizzazione potenziati per anatomia e funzione cardiaca. Il sistema è pensato per supportare i team di cardiologia nella gestione di volumi di pazienti e complessità cliniche crescenti, mantenendo al contempo accuratezza diagnostica, in particolare nella valutazione della funzione ventricolare sinistra.
Transcend Plus sarà in mostra al Congresso 2025 della European Society of Cardiology e all'incontro annuale della American Society of Echocardiography.
Philips (NYSE:PHG) ha lanzado Transcend Plus, una importante actualización para sus sistemas de ecografía cardiovascular EPIQ CVx y Affiniti CVx. La nueva plataforma incorpora mejoras de imagen 2D y 3D aprobadas por la FDA y 26 aplicaciones clínicas con IA, la cifra más alta del sector.
Entre las innovaciones destaca la nueva función 2D Auto EF Advanced, que amplía las capacidades de IA a las imágenes con contraste, y herramientas de visualización mejoradas para la anatomía y función cardíaca. El sistema está diseñado para ayudar a los equipos de cardiología a gestionar mayores volúmenes de pacientes y una mayor complejidad clínica sin sacrificar la precisión diagnóstica, especialmente en la evaluación de la función ventricular izquierda.
Transcend Plus se presentará en el Congreso 2025 de la European Society of Cardiology y en la reunión anual de la American Society of Echocardiography.
Philips (NYSE:PHG)는 EPIQ CVx 및 Affiniti CVx 심혈관 초음파 시스템을 위한 대규모 업그레이드인 Transcend Plus를 공개했습니다. 새 플랫폼은 FDA 승인된 2D·3D 영상 향상과 업계 최다인 26개의 AI 기반 임상 애플리케이션을 제공합니다.
주요 기능으로는 대비 에코(contrast) 영상까지 AI 적용 범위를 확대한 새로운 2D Auto EF Advanced와 심장 해부 및 기능에 대한 시각화 도구 개선이 포함됩니다. 이 시스템은 심장팀이 증가하는 환자 수와 복잡한 임상 상황을 관리하면서도 특히 좌심실 기능 평가에서 진단 정확도를 유지하도록 설계되었습니다.
Transcend Plus는 유럽심장학회(ESC) 2025 총회와 미국심초음파학회(ASE) 연례 학술대회에서 공개될 예정입니다.
Philips (NYSE:PHG) a dévoilé Transcend Plus, une mise à niveau majeure de ses systèmes d'échographie cardiovasculaire EPIQ CVx et Affiniti CVx. La nouvelle plateforme intègre des améliorations de l'imagerie 2D et 3D approuvées par la FDA et 26 applications cliniques assistées par IA, soit le plus grand nombre du secteur.
Parmi les nouveautés, la fonction 2D Auto EF Advanced étend les capacités d'IA aux images avec contraste, et des outils de visualisation améliorés facilitent l'analyse de l'anatomie et de la fonction cardiaques. Le système vise à aider les équipes de cardiologie à gérer l'augmentation des volumes de patients et la complexité clinique tout en préservant la précision diagnostique, en particulier pour l'évaluation de la fonction ventriculaire gauche.
Transcend Plus sera présenté au Congress 2025 de la European Society of Cardiology et à la réunion annuelle de l'American Society of Echocardiography.
Philips (NYSE:PHG) hat Transcend Plus vorgestellt, ein bedeutendes Upgrade für die kardiovaskulären Ultraschallsysteme EPIQ CVx und Affiniti CVx. Die neue Plattform bietet FDA-zugelassene Verbesserungen der 2D- und 3D-Bildqualität sowie 26 KI-gestützte klinische Anwendungen – die höchste Zahl in der Branche.
Zu den wichtigsten Innovationen gehört die neue 2D Auto EF Advanced-Funktion, die KI-Fähigkeiten auf Kontrastbilder ausweitet, sowie verbesserte Visualisierungstools für Herzstruktur und -funktion. Das System soll Kardiologieteams unterstützen, steigende Patientenzahlen und zunehmende klinische Komplexität zu bewältigen und dabei die diagnostische Genauigkeit, insbesondere bei der Beurteilung der linksventrikulären Funktion, zu erhalten.
Transcend Plus wird auf dem European Society of Cardiology Congress 2025 und dem Jahrestreffen der American Society of Echocardiography vorgestellt.
- Industry-leading portfolio of 26 FDA-cleared cardiovascular ultrasound AI applications
- Enhanced 2D and 3D imaging quality with latest FDA clearance
- New AI-powered 2D Auto EF Advanced feature for improved contrast imaging
- System supports approximately 1.33 billion procedures annually worldwide
- None.
Insights
Philips' Transcend Plus cardiovascular ultrasound platform enhances diagnostic capabilities with 26 FDA-cleared AI applications, strengthening their market position.
Philips has made a significant advancement in cardiovascular diagnostics with the launch of Transcend Plus for their EPIQ CVx and Affiniti CVx ultrasound systems. The platform introduces superior image quality enhancements and 26 FDA-cleared AI applications – the most in the industry according to Philips – addressing critical challenges in cardiac care delivery.
The technology focuses on streamlining left ventricular function assessment, one of the most crucial diagnostic parameters in cardiology. The 2D Auto EF and 2D Auto EF Advanced features enable consistent, reproducible measurements for both contrast and non-contrast studies, reducing operator variability that has traditionally plagued cardiac ultrasound.
What makes this release particularly valuable is its timing amid healthcare's triple challenge: increasing patient volumes, rising clinical complexity, and persistent staffing shortages. The AI automation can standardize measurements across different operators and patients, potentially reducing examination time while maintaining diagnostic accuracy.
The endorsement from Dr. Akhil Narang, Director of Northwestern University's Echocardiography Laboratory, adds clinical credibility, highlighting how AI can transform manual, time-consuming processes into fast, reproducible measurements. With Philips ultrasound systems reportedly performing 1.33 billion procedures annually for 654 million patients, even incremental efficiency improvements could significantly impact clinical outcomes and workflow productivity.
This launch reinforces Philips' strategy of maintaining leadership in cardiovascular ultrasound through continuous innovation, particularly by integrating AI capabilities that enhance rather than replace clinician expertise. The development addresses both the technical limitations of traditional echocardiography and the practical challenges facing cardiology departments globally.
August 27, 2025
Next-generation 2D and 3D imaging and intelligent automation empower clinicians to make faster, more confident decisions in cardiac care
Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the release of Transcend Plus, the next generation its EPIQ CVx and Affiniti CVx cardiovascular ultrasound systems. Transcend Plus delivers major advancements in image quality and artificial intelligence (AI), including newly FDA-cleared 2D and 3D image quality enhancements and a growing suite of AI-enabled clinical applications – all designed to meet the growing challenges of cardiac care delivery. With increased patient volume, rising clinical complexity, and persistent staffing shortages, Transcend Plus is designed to help cardiology teams work smarter, not harder – offering fast, reproducible results with uncompromising image quality and decision-making support.
"Transcend Plus represents a bold leap forward in the evolution of echocardiography, reinforcing our commitment to continuous innovation, empowering clinicians with AI-driven tools that enhance confidence, accelerate decision-making, and elevate care at every stage of the cardiac journey,” said David Handler, Business Leader, Cardiology Ultrasound at Philips. “Transcend Plus is more than an advancement – it’s a clear statement of Philips’ leadership in cardiovascular ultrasound. Building on the momentum of our original Transcend launch, Transcend Plus brings the full power of AI integration to the forefront, giving clinicians the confidence, speed, and precision they need to lead in cardiac care – today and into the future.”
Industry-leading image quality now enhanced
Transcend Plus visibly improves sharpness, contrast, and detail in 2D and 3D imaging, featuring the latest FDA-cleared enhancements for EPIQ CVx and Affiniti CVx. These upgrades support superior visualization of cardiac anatomy and function, enabling diagnostic confidence even in the most complex or technically challenging cases. The update also introduces the new 2D Auto EF Advanced feature, expanding AI capabilities for contrast images – essential for accurately assessing cardiac function.
“Artificial intelligence is a tool, not a threat, and I always maintain that human plus AI is going to be better than human alone or AI alone – the 3D Auto CFQ and 3D Auto TV AI applications are examples of this, taking manual, time-consuming processes and automating these measurements in a fast, easy and reproducible way,” said Akhil Narang, MD, Director, Echocardiography Laboratory and Associate Professor of Medicine, Division of Cardiology at the Feinberg School of Medicine, Northwestern University and Bluhm Cardiovascular Institute.
26 FDA-cleared AI applications, now fully integrated
Philips now offers 26 FDA-cleared cardiovascular ultrasound AI applications – the most in the industry – fully integrated into Transcend Plus for both EPIQ and Affiniti CVx systems. Among the latest enhancements to receive FDA 510(k) clearance are 2D Auto EF and 2D Auto EF Advanced. These advanced tools are designed to streamline clinical workflows and improve diagnostic accuracy across a range of care settings, from the echo lab through the hospital to outpatient clinics, pre-assessment, and long-term follow-up. With these integrated AI applications, clinicians can assess patients more quickly, consistently, and confidently across the entire care continuum.
Why left ventricular function assessment matters
Left ventricular (LV) function assessment is one of the most critical applications in cardiac imaging, playing a central role in diagnosing and managing a wide range of cardiac conditions. Transcend Plus directly supports this need by delivering fast, reproducible results that help cardiologists quickly and definitively evaluate LV function consistently across different patients and over time. Automated tools minimize operator variability, ensuring more reliable and standardized measurements, especially vital in high-volume or high-pressure clinical environments. In addition, Transcend Plus offers robust support for both contrast and non-contrast imaging. The 2D Auto EF feature enables accurate assessments even when contrast agents cannot be used, such as in patients with renal impairment. Building on this, 2D Auto EF Advanced adds AI-powered quantification capabilities for both contrast and non-contrast studies, broadening clinical applicability and enhancing measurement reliability in patients with poor image quality or challenging acoustic windows. These capabilities combine to deliver a more confident, efficient approach to cardiac care.
Clinical confidence, anywhere, anytime
Transcend Plus empowers clinicians to make fast, confident decisions across every cardiac care setting – whether in the echo lab, interventional suite, or during routine outpatient assessments. By delivering sharper imaging and intelligent automation, it enables more informed care, streamlines workflows, and helps providers manage growing patient volumes without compromising diagnostic quality or clinician well-being. Transcend Plus delivers three core benefits: enhanced image quality for clearer visualization of cardiac anatomy and improved diagnostic precision; advanced AI integration, with 26 FDA-cleared applications that automate and accelerate routine tasks; and faster, more actionable insights that reduce delays and support timely, evidence-based clinical decisions throughout the care journey.
Philips Ultrasound systems installed around the world perform an estimated 1.33 billion diagnostic and interventional procedures each year, supporting diagnosis and treatment for 654 million unique patients annually. Transcend Plus will be demonstrated live at the European Society of Cardiology 2025 Congress (ESC) in Madrid (Aug. 29 – Sept. 1) and the American Society of Echocardiography annual meeting (ASE) in Nashville (Sept. 5 – Sept. 7), offering hands-on clinical insight into how these innovations are transforming cardiac ultrasound. Visit Philips Cardiovascular Ultrasound for more information.
For further information, please contact:
Kathy O’Reilly
Philips Global External Relations
Tel.: +1 978-221-8919
E-mail: kathy.oreilly@philips.com
Joost Maltha
Philips Global External Relations
Tel.: +31 6 1055816
E-mail: joost.maltha@philips.com
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.
Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2024 sales of EUR 18 billion and employs approximately 67,300 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.
Attachments
- Transcend Plus Ultrasound system in use
- EPIQ CVx system clinical view
- Mini 3D TEE transducer clinical view
FAQ
What are the key features of Philips' new Transcend Plus cardiovascular ultrasound system?
How many FDA-cleared AI applications does Philips Transcend Plus include?
What is the significance of the 2D Auto EF Advanced feature in Transcend Plus?
Where will Philips demonstrate the new Transcend Plus system?
How many procedures do Philips Ultrasound systems support globally?
